JP2009544724A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544724A5
JP2009544724A5 JP2009521935A JP2009521935A JP2009544724A5 JP 2009544724 A5 JP2009544724 A5 JP 2009544724A5 JP 2009521935 A JP2009521935 A JP 2009521935A JP 2009521935 A JP2009521935 A JP 2009521935A JP 2009544724 A5 JP2009544724 A5 JP 2009544724A5
Authority
JP
Japan
Prior art keywords
antigen
composition
cytokine
csf
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544724A (ja
Filing date
Publication date
Priority claimed from US11/492,418 external-priority patent/US20070025958A1/en
Application filed filed Critical
Publication of JP2009544724A publication Critical patent/JP2009544724A/ja
Publication of JP2009544724A5 publication Critical patent/JP2009544724A5/ja
Pending legal-status Critical Current

Links

JP2009521935A 2006-07-25 2007-07-24 ワクチン免疫療法 Pending JP2009544724A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/492,418 US20070025958A1 (en) 2000-10-27 2006-07-25 Vaccine immunotherapy
PCT/US2007/074156 WO2008014220A2 (en) 2006-07-25 2007-07-24 Vaccine immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013140691A Division JP2013189480A (ja) 2006-07-25 2013-07-04 ワクチン免疫療法

Publications (2)

Publication Number Publication Date
JP2009544724A JP2009544724A (ja) 2009-12-17
JP2009544724A5 true JP2009544724A5 (enExample) 2010-08-19

Family

ID=38982244

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009521935A Pending JP2009544724A (ja) 2006-07-25 2007-07-24 ワクチン免疫療法
JP2013140691A Withdrawn JP2013189480A (ja) 2006-07-25 2013-07-04 ワクチン免疫療法
JP2015222533A Expired - Fee Related JP6162778B2 (ja) 2006-07-25 2015-11-12 ワクチン免疫療法
JP2017117390A Pending JP2017155059A (ja) 2006-07-25 2017-06-15 ワクチン免疫療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013140691A Withdrawn JP2013189480A (ja) 2006-07-25 2013-07-04 ワクチン免疫療法
JP2015222533A Expired - Fee Related JP6162778B2 (ja) 2006-07-25 2015-11-12 ワクチン免疫療法
JP2017117390A Pending JP2017155059A (ja) 2006-07-25 2017-06-15 ワクチン免疫療法

Country Status (7)

Country Link
US (3) US20070025958A1 (enExample)
EP (2) EP2684569A1 (enExample)
JP (4) JP2009544724A (enExample)
AU (1) AU2007276835B2 (enExample)
CA (1) CA2694428C (enExample)
MX (1) MX2009000934A (enExample)
WO (1) WO2008014220A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
EP2276850B9 (en) * 2008-04-14 2013-10-30 IRX Therapeutics, Inc. Irx-2 modified manufacturing process
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
AU2009251277A1 (en) * 2008-05-29 2009-12-03 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
EP2429585B1 (en) * 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Vaccine immunotherapy
AU2013203561B2 (en) * 2009-05-15 2015-11-26 Irx Therapeutics, Inc. Vaccine immunotherapy
EP2498795B1 (en) 2009-10-12 2016-12-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Granulysin in immunotherapy
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012021609A2 (en) * 2010-08-12 2012-02-16 Ulrik Mouritzen Neoadjuvant treatment of cancer with proleukin
WO2012037551A2 (en) * 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US20150284444A1 (en) * 2012-02-16 2015-10-08 Masami Watanabe Pharmaceutical composition for cancer treatment including fusion protein
CN104122710B (zh) * 2013-04-27 2017-08-08 北京京东方光电科技有限公司 一种显示面板及其制造方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018161038A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
US11464798B2 (en) 2017-05-11 2022-10-11 Theralase Technologies Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
CN110101843A (zh) * 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
WO2020073044A1 (en) * 2018-10-05 2020-04-09 Czerniecki Brian J Combination therapy for treating cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (enExample) * 1971-11-19 1975-02-07 Anvar
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4470926A (en) * 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4293455A (en) * 1980-04-07 1981-10-06 Rockefeller University N.sup.α -Desacetylthymosinα1 and process
GR74132B (enExample) 1980-05-22 1984-06-06 Deutsches Krebsforsch
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4406830A (en) * 1981-04-17 1983-09-27 Shanksville Corporation, N.V. Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
DE3120912A1 (de) * 1981-05-26 1982-12-16 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von p-nitrophenetol
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4614731A (en) * 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) * 1983-10-27 1987-04-21 Hoffmann-La Roche Inc. Prothymosin alpha
US4716148A (en) * 1984-08-13 1987-12-29 Hoffman-La Roche Inc. Prothymosin alpha
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
WO1987006830A1 (en) 1986-05-09 1987-11-19 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
US4992367A (en) 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
SE8801426D0 (sv) 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
JPH08511166A (ja) 1993-06-04 1996-11-26 アメリカ合衆国 T細胞の増殖を選択的に刺激する方法
DE69434475T2 (de) * 1993-08-11 2006-05-18 Jenner Technologies, Tiburon Impfstoff gegen prostatakrebs
CN1044781C (zh) 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
EP0789588B1 (en) 1994-11-17 2005-01-19 University Of South Florida Method for making a medicament for treating secondary immunodeficiency
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
DE69628921T2 (de) 1995-05-04 2004-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Navy Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AP964A (en) 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
EP1027453A4 (en) * 1997-10-17 2004-12-01 Univ South Florida METHOD FOR DIAGNOSIS AND MONITORING OF CELLULAR IMMUNE FUNCTIONS
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
PT1053017E (pt) 1998-02-12 2004-12-31 Wyeth Corp Vacinas compreendendo interleucina-12 e antigenio de virus herpes simplex
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
EP0974357A1 (en) 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6350589B1 (en) * 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US7056503B2 (en) * 1999-08-19 2006-06-06 Regents Of The University Of Michigan Enclosures housing cell-coated supports for treating tumors
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
KR20030032922A (ko) * 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
CN1437481A (zh) * 2000-06-22 2003-08-20 美国氰胺公司 作为佐剂组合的qs-21和il-12
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
AU2002232560A1 (en) * 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US7731945B2 (en) * 2001-10-26 2010-06-08 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
DE10154579A1 (de) * 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
EP1469860A4 (en) 2002-01-24 2005-09-07 Yissum Res Dev Co ANTICANCER COMBINATION AND USE THEREOF
MXPA05006945A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
CN1802174A (zh) * 2003-04-15 2006-07-12 圣诺菲·帕斯图尔有限公司 用于预防和/或治疗癌症的肿瘤抗原bfa5
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20070196335A1 (en) 2004-02-09 2007-08-23 The Johns Hopkins University Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
CN101005760A (zh) 2004-06-04 2007-07-25 塞尔-赛公司 改变cd4/cd8和进入肿瘤的单核细胞浸润液的方法
WO2005123120A1 (en) 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
US20060140983A1 (en) 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
AU2006292203A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
KR20220113543A (ko) 2005-12-08 2022-08-12 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
US20070259330A1 (en) * 2006-05-04 2007-11-08 Ge Healthcare Bio-Sciences Ab Separation of cells
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8802098B2 (en) 2007-04-25 2014-08-12 Immurx, Inc. Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
DK2234642T3 (en) * 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
EP2276850B9 (en) 2008-04-14 2013-10-30 IRX Therapeutics, Inc. Irx-2 modified manufacturing process
AU2009251277A1 (en) 2008-05-29 2009-12-03 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
EP2429585B1 (en) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Vaccine immunotherapy
CN103097543A (zh) * 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US20130243423A1 (en) * 2011-07-26 2013-09-19 Ziqiang He Ethernet hub and method of use

Similar Documents

Publication Publication Date Title
JP2009544724A5 (enExample)
Maniati et al. Up for Mischief? IL-17/Th17 in the tumour microenvironment
Kurzrock Cytokine deregulation in cancer
JP2005530716A5 (enExample)
Yuzhalin et al. Interleukin-12: clinical usage and molecular markers of cancer susceptibility
Asadullah et al. Cytokines: interleukin and interferon therapy in dermatology
JP2012087150A5 (enExample)
WO2008014220A3 (en) Vaccine immunotherapy
EA201791519A1 (ru) Новая иммунотерапия против нейрональных опухолей и опухолей головного мозга
JP2002524537A5 (enExample)
EP2172212A3 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
Kaufman et al. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity
MXPA02000490A (es) Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
EP2420249A1 (en) Vaccine immunotherapy for immune suppressed patients
JP2007501798A5 (enExample)
KR100788930B1 (ko) 항암 조성물
Autenshlyus et al. Cytokine pattern of the breast tumor supernatant
Hofbauer et al. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate
Ito et al. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate
Pérez-Torres et al. Hematological effects, serum, and pulmonary cytokine profiles in a melanoma mouse model treated with GK1
Cui et al. Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells
Jin et al. Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects
Sonn et al. MethA fibrosarcoma cells expressing membrane-bound forms of IL-2 enhance antitumor immunity
Fridman et al. The use of cytokines in the treatment of solid tumours
Jetten et al. 87. Modulation of growth and differentiation in human epidermal and tracheobronchial keratinocytes by interferon γ